Xbrane Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was SEK 45.47 million compared to SEK 57.74 million a year ago. Basic loss per share was SEK 1.83 compared to SEK 2.99 a year ago. Diluted loss per share was SEK 1.83 compared to SEK 2.99 a year ago. For the nine months, net loss was SEK 155.91 million compared to SEK 162.97 million a year ago. Basic loss per share was SEK 6.75 compared to SEK 9.49 a year ago. Diluted loss per share was SEK 6.75 compared to SEK 9.49 a year ago.